NY-700

N/A

Report date: 2026/04/23 11:24:53

Base Information

Drug NameNY-700

Drug Alias NameGPC3-targeted Astatine-211 (211At) alpha radioimmunotherapyNY-700

ClassificationRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionGlypican-3 binders

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNAYA Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesNAYA Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A